Boserolimab clinical trials
Also written MK-5890.
How each study uses boserolimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the boserolimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Anti-ILT4 Monoclonal Antibody MK-4830 (3) · Rolistobart (2) · Lenvatinib (1) · Vibostolimab (1) · Ifinatamab deruxtecan (1) · Patritumab deruxtecan (1)
Studies
Open first, then newest update. How each study uses boserolimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as BoserolimabReport a problem
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)CompletedPhase 2Merck Sharp & Dohme LLCNCT04924101Written as BoserolimabReport a problem
- KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)CompletedPhase 2Merck Sharp & Dohme LLCNCT04165096Written as BoserolimabReport a problem
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)WithdrawnPhase 2Merck Sharp & Dohme LLCNCT06829199Written as BoserolimabReport a problem
- Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT03396445Written as BoserolimabReport a problem
Tested with established drugs · 2 — they are given beside it
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)WithdrawnPhase 2Merck Sharp & Dohme LLCNCT06829199Written as BoserolimabReport a problem
- Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT03396445Written as BoserolimabReport a problem
Tested in a combination · 3 — another drug in the study is under test too
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as BoserolimabReport a problem
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)CompletedPhase 2Merck Sharp & Dohme LLCNCT04924101Written as BoserolimabReport a problem
- KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)CompletedPhase 2Merck Sharp & Dohme LLCNCT04165096Written as BoserolimabReport a problem
Codes
What other systems call boserolimab · ClinicalTrials.gg INT015025
- UNII (FDA) 576SCZ7V2PBOSEROLIMABOne source FDA
- NCI Thesaurus C172056BoserolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 576SCZ7V2P | BOSEROLIMAB | One source FDA |
| NCI Thesaurus | C172056 | Boserolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.